VYNE Therapeutics Q2 net loss $10.1M; VYN201 phase 1b data due Q3 2023

VYNE Therapeutics Inc.

2023-Q2 EPS reported -$4.82 revenue$234,000

Net loss of $10.1M ($3.09 per share) vs $8.5M ($2.63) in Q2 2022; revenue flat at $0.1M.
Cash and restricted cash $20.7M as of June 30, 2023; expects to fund operations through end of 2023.
R&D expenses rose to $7.2M from $4.1M YoY, primarily due to VYN202 license payment and development costs.
VYN201 Phase 1b preliminary safety/efficacy data in nonsegmental vitiligo anticipated in Q3 2023.
VYN202 IND submission expected by year-end; Phase 1 trial to begin Q1 2024.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.95

VYNE Therapeutics Inc. reported the three and six months ended June 30, 2023 results: net income Net loss and net loss per share for the quarter ended June 30, 2023 was $10.1 million and $3.09.

Period: the three and six months ended June 30, 2023
Net income: Net loss and net loss per share for the quarter ended June 30, 2023 was $10.1 million and $3.09
Result: reported results

Exact text from the filing

VYNE Therapeutics Inc. (Nasdaq: VYNE) (“VYNE” or the “Company”), a clinical-stage biopharmaceutical company focused on developing proprietary, innovative and differentiated therapies for the treatment of immuno-inflammatory conditions, today announced financial results for the three and six months ended June 30, 2023 and provided a business update.

View on SEC.gov

Browse all earnings releases →

VYNE Therapeutics Inc. filing history →

Source: SEC EDGAR

accession 0001628280-23-029193

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.